Show simple item record

AuthorFatima, Kaneez
AuthorMathew, Shilu
AuthorFaheem, Muhammed
AuthorMehmood, Tahir
AuthorYassine, Hadi Mohamad
AuthorAl Thani, Asmaa A
AuthorAbdel-Hafiz, Hany
AuthorAl Ghamdy, Khalid
AuthorQadri, Ishtiaq
Available date2018-09-23T07:04:29Z
Publication Date2018-09
Publication NameCurrent Pharmaceutical Design
Identifierhttp://dx.doi.org/10.2174/1381612824666180911114210
CitationKaneez Fatima, Shilu Mathew, Muhammed Faheem, Tahir Mehmood, Hadi Mohamad Yassine, Asmaa A. Al Thani, Hany Abdel-Hafiz, Khalid Al Ghamdy and Ishtiaq Qadri*. Current Pharmaceutical Design (2018) 24: 1. https://doi.org/10.2174/1381612824666180911114210
ISSN1381-6128
URIhttp://hdl.handle.net/10576/11096
AbstractThe FOXO (Forkhead box O) transcription factors are implicated in several signaling pathways and play a vital role in various cellular and physiological processes include for instance, ROS (reactive oxygen species) response, cell proliferation, regulation of programmed cell death, longevity, metabolism and cancer and regulation of cell cycle. In humans, the four FOXO family members are responsible for resemblance in their structure, regulation and functions. FOXO1 gene is highly expressed in adipose tissues and it affects the regulation of glycogenolysis and gluconeogenesis through insulin signaling. The gene of FOXO3 is highly expressed in the kidney, heart, spleen and brain and is characterized as diverse forkhead DNA-binding domain of transcription factors. The FOXO3 is a tumor suppressor gene and found to interact with p53, the trigger for apoptosis through BCl2 family genes and a regulator of Notch signaling pathway for the self-renewal of stem cells. Therefore, FOXOs remains to be a fascinating and potential target to acquire novel therapeutic approaches to cure cancer. This review will provide a comprehensive overview about the biology of FOXO proteins, which can be utilized for developing current therapeutic approaches to treat cancer.
Languageen
PublisherBentham Science Publishers
SubjectForkhead box O
Therapeutic
Cancer
Polymorphism
Transcription factors
TitleThe Dual Specificity Role of Transcription Factor FOXO in Type 2-diabetes and Cancer
TypeArticle Review
Pagination1-10
Volume Number24
ESSN1873-4286
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record